HC
Health Catalyst, Inc.
HCAT · NASDAQ
$1.76 +0.57% (+$0.01)
1M +2.94%
Market Cap $130.1M
P/E Ratio -
Div. Yield -
ROE 129.71%
Bulios Fair Price
$2.55
44.9% upside
Current Price
$1.76
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HCAT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
100 /100
Cheap P/S 0.45x
P/FCF 9.96x
P/B 1.29x
Growth
31 /100
Declining Rev. growth 4.05%
Book val. growth 16.69%
EPS growth N/A
Profitability
29 /100
Weak Gross margin 46.44%
FCF margin 4.47%
Net margin 90.61%
Quality
10 /100
Poor ROIC 21.22%
Asset turnover 0.81x
ROE 129.71%
Debt
36 /100
Moderate Debt/Equity 1.69x
Int. coverage -12.06x
Current ratio 2.70x
Stability
39 /100
Moderate Beta 1.53x
Profitable years 0
Rev. volatility 2.85%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HCAT
Online
Sector
Healthcare
Industry
Medical - Healthcare Information Services
CEO
Benjamin Albert
Employees
1,200
Headquarters
South Jordan
Upcoming events
09 NOV
Earnings
Upcoming earnings report